Navigation Links
Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/28/2008

SAN DIEGO, April 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008 at 9:50 a.m. Eastern Time (6:50 a.m. Pacific Time) at the Ritz-Carlton in Key Biscayne, Florida. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... D.C. (PRWEB) , ... February 11, 2016 , ... ... will be exhibiting at the American Academy of Dermatology Annual Meeting at the ... USA's goal is to raise awareness for both the condition of hyperhidrosis (excessive ...
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... was held in San Diego, CA, on February 6th & 7th, 2016 according to ... for those who were not invited to the NFL’s combine in Indianapolis,” says Husted. ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on ... before signing a contract and how to spot an incompetent or dishonest IT person ... e-mail and technology, it’s more important than ever to make sure the company you ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual ... Imaging Congress (WMIC), will be held in New York City, NY on September ... Therapy.” The congress will highlight and emphasize how imaging reveals a greater understanding ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... 2016   Genomic Health, Inc. (Nasdaq: GHDX ) ... year ended December 31, 2015. --> ... 2015, compared with $69.1 million in the fourth quarter of 2014, ... increased 9 percent compared with the same period in the prior ... was $63.9 million in the fourth quarter of 2015, an increase ...
Breaking Medicine Technology: